Combinations Key For Amgen’s Lumakras, But PD-1/L1 Data Held Until August
Combo Importance Increases With Sales Growth Slowing
Executive Summary
A World Conference on Lung Cancer abstract shows responses to Lumakras with a SHP2 inhibitor but closely watched results for anti-PD-1/L1 combinations are under embargo until the meeting next month.
You may also be interested in...
Can Amgen Balance Efficacy, Safety With KRAS/PD-1 Combination?
Data presented during the weekend at WCLC for Lumakras with Keytruda or Tecentriq raised questions about elevated liver toxicity and a lackluster response rate.
Finance Watch: Recent M&A Uptick Gives Biopharma A Needed Boost
Public Company Edition: William Blair analysts note that stock prices are rising due to a Q2 boost in dealmaking after a lull in Q1. Nevertheless, layoffs and portfolio prioritizations are ongoing, including at X4 Pharmaceuticals, but others have raised cash following good news, like Revolution Medicines.
Mirati Seeks Differentiation, Amgen Invests In Combos To Dominate KRAS G12C Field
Amgen outlined the most frequent co-mutations in treatment-resistant lung and colorectal cancers at ASCO, while Mirati’s adagrasib showed efficacy in active CNS metastases in lung cancer patients.